| 000 | 01246cam a2200193 4500500 | ||
|---|---|---|---|
| 005 | 20250121143414.0 | ||
| 041 | _afre | ||
| 042 | _adc | ||
| 100 | 1 | 0 |
_avon der Weid, Guillaume _eauthor |
| 245 | 0 | 0 | _aCan we defend the drug industry? |
| 260 | _c2018. | ||
| 500 | _a62 | ||
| 520 | _aThe drug industry has a poor public image. Although its role is to treat disease, it has a poorer reputation than cigarette makers or the automotive industry. This situation must be analysed from three overlapping points of view: 1) the complexity of a market, in which most of the costs are hidden; 2) the difficulty of a connected society to organize debates on political questions related to basic values, and finally 3) the pervading distinction between morality and profits. This clarification might help the industry to become a fully fledged actor in the field of healthcare in order to participate in the improvement of the healthcare offer for the population. | ||
| 690 | _adrug industry | ||
| 690 | _acommodification | ||
| 690 | _acosts and cost analysis | ||
| 786 | 0 | _nSanté Publique | 30 | 1 | 2018-03-14 | p. 101-103 | 0995-3914 | |
| 856 | 4 | 1 | _uhttps://shs.cairn.info/journal-sante-publique-2018-1-page-101?lang=en&redirect-ssocas=7080 |
| 999 |
_c587063 _d587063 |
||